Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot received authorization from the U.S. Food and Drug Administration (FDA). This shot shields infants up to the age of one from the respiratory syncytial virus during their first RSV period. RSV refers to a common respiratory virus that leads to seasonal infections like the flu, yet for infants and older people, it is a primary cause of pneumonia and death.

There has been limited availability of Sanofi’s and AstraZeneca’s preventive shots for RSV for the previously mentioned age group so far. Merck’s antibody, called clesrovimab and sold under the name Enflonsia, can be taken as a single dose to protect healthy pre-term, full-term, and at-risk infants from mild to aggressive RSV.

Merck & Co., Inc. (NYSE:MRK) projects Enflonsia shipments to turn up on schedule for the 2025-2026 RSV season. The CDC’s Advisory Committee on Immunization Practices will likely gather later in June to assess and recommend the use of Enflonsia for infants.

Merck is a global healthcare company that develops treatments for cancer, infectious diseases, and chronic conditions, and also provides vaccines and health solutions for both humans and animals.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.